Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has approved “Vabysmo”… Read More »Genentech (Roche Group) has reported approval from FDA for faricimab-svoa for the treatment of macular edema following Retinal Vein Occlusion (RVO).
Researchers at UCL and Moorfields Eye Hospital, UK, have reported clinical research using artificial intelligence (AI) tools to identify at-risk neonates of retinopathy of prematurity… Read More »Clinical research at UCL and Moorfields on AI tools to identify at-risk neonates of retinopathy of prematurity (ROP).
Researchers at the Herbert Wertheim School of Optometry and Vision Science, Science, University of California, Berkeley, have reported a rare type retinal output neurons called… Read More »Research studies of ON-type direction-selective ganglion cells may originate from some forms of nystagmus.
by Dr. Gearóid Tuohy Dear EURETINA Members, A very warm welcome to the December 19th, 2023 edition of EURETINA’s web-based digital magazine, “EURETINA Brief”. EURETINA… Read More »December 19th, 2023 “EURETINA-Brief”© Issue No. 283
OliX Pharmaceuticals (KOSDAQ: 226950), based in Gyeonggi-do, Seoul, Republic of South Korea, has announced positive results from a phase 1 study evaluating the safety and… Read More »OliX Pharmaceuticals have announced positive results for an siRNA experimental treatment for AMD.
A recent update on phase 2 clinical research of a novel treatment for patients of Stargardt disease has reported a positive primary end-point slowing the… Read More »Clinical research on a novel oral therapy for Stargardt disease suggests uses a deuterated form of vitamin A.
Researchers at the Eye Research Institute, Anglia Ruskin University, Cambridge, UK, have published a report highlighting a correlation between registered clinical studies on leading causes… Read More »Research studies focusing on causes of severe sight impairment (SSI) certifications correlated to the number of clinical studies registered in the UK.
by Dr. Gearóid Tuohy Dear EURETINA Members, A very warm welcome to the December 1st, 2023 edition of EURETINA’s web-based digital magazine, “EURETINA Brief”. EURETINA… Read More »December 1st, 2023 “EURETINA-Brief”© Issue No. 282
Opus Genetics Inc., a private ocular gene therapy company based in Raleigh, North Carolina, has announced a first-patient-dosed for a Phase 1/2 clinical trial. This… Read More »Opus Genetics Inc., has announced a first-patient-dosed in a Phase 1/2 trial for “OPGx-LCA5” for the treatment of LCA5 retinal disease.
Researchers at the Institute for Vision Research, University of Iowa, USA, and Ophthalmology and Visual Sciences, Duke-NUS Graduate Medical School, Singapore, have reported a publication… Read More »Research on clinical trial outcomes for XLRS have proposed prolonged trial periods in order to assess disease stabilization.
